Droxia Related Clinical Trials
Imatinib Mesylate and Hydroxyurea in Treating Patients With Recurrent or Progressive Meningioma [Completed]
Ph I Zactima + Imatinib Mesylate & Hydroxyurea for Pts w Recurrent Malignant Glioma [Completed]
Pharmacokinetics (PK) of Liquid Hydroxyurea in Pediatric Patients With Sickle Cell Anemia [Completed]
Ph I Gleevec in Combo w RAD001 + Hydroxyurea for Pts w Recurrent MG [Completed]
Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) [Completed]
Realizing Effectiveness Across Continents With Hydroxyurea (REACH) [Recruiting]
Sickle Cell Disease - Stroke Prevention in Nigeria Trial [Active, not recruiting]
Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease [Recruiting]
Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin. [Not yet recruiting]
Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera [Completed]
Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma [Completed]
Transcranial Doppler (TCD) With Transfusions Changing to Hydroxyurea [Active, not recruiting]
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma [Completed]
Inflammatory Response to Hydroxyurea Therapy in Sickle Cell Disease [Completed]
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) [Recruiting]
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms [Recruiting]
Sparing Conversion to Abnormal TCD (Transcranial Doppler) Elevation (SCATE) [Terminated]
Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM) [Terminated]
Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer [Completed]
A Dose Escalation Study of Hydroxyurea in Combination With SCH900776 in Advanced Malignant Solid Tumors [Withdrawn]
Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera [Active, not recruiting]
Risk Clinical Stratification of Sickle Cell Disease in Nigeria, Assessment of Efficacy/Safety of Hydroxyurea Treatment [Enrolling by invitation]
Therapeutic Response Evaluation and Adherence Trial (TREAT) [Recruiting]
Novel Dose Escalation to Predict Treatment With Hydroxyurea [Recruiting]
Hydroxyurea in Pulmonary Arterial Hypertension [Withdrawn]
Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML [Recruiting]
Novel Use Of Hydroxyurea in an African Region With Malaria [Recruiting]
Evaluating the Safety of G-CSF Mobilization in Individuals With Beta Thalassemia Major [Completed]
Long Term Effects of Hydroxyurea Therapy in Children With Sickle Cell Disease [Active, not recruiting]
Hydroxyurea in Young Children With Sickle Cell Anemia [Completed]
Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment: HABIT [Recruiting]
Primary Thrombocythaemia 1 Trial [Active, not recruiting]
Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia [Completed]
Stroke With Transfusions Changing to Hydroxyurea [Terminated]
Hydroxyurea in Primary Progressive Multiple Sclerosis [Terminated]
Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators [Recruiting]
The Safety and Effectiveness of Hydroxyurea and ddI Used Individually or Together in HIV-Infected Patients [Completed]
Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated [Completed]
Hydroxyurea With or Without Imatinib Mesylate in Treating Patients With Recurrent or Progressive Meningioma [Recruiting]
Treatment of Hemoglobin SC Disease [Recruiting]
Effectiveness of Early or Delayed Addition of Hydroxyurea to a Three-Drug Anti-HIV Drug Combination Including Didanosine, in Advanced HIV Patients Who Failed a First or Second Anti-HIV Triple-Drug Therapy [Withdrawn]
Effect of Hydroxyurea as Treatment for Primary Desmoid Tumors [Withdrawn]
Phase II of Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma [Recruiting]
S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma [Completed]
Hydroxyurea and Erythropoietin to Treat Sickle Cell Anemia [Completed]
Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease [Terminated]
Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease [Recruiting]
Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa [Terminated]
Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease [Completed]
Hydroxyurea for Children and Young Adults With Sickle Cell Disease and Pulmonary Hypertension [Terminated]
Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection [Withdrawn]
A Randomized, Placebo-Controlled Study of the Safety and Efficacy of Efavirenz, Didanosine, and Stavudine in Combination With or Without Hydroxyurea in Antiretroviral Naive or Experienced HIV-Infected Patients [Completed]
A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood [Completed]
Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004) [Completed]
Combination of Hydroxyurea and Verapamil for Refractory Meningiomas [Active, not recruiting]
Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) [Not yet recruiting]
A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients [Active, not recruiting]
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer [Recruiting]
PHASE III TRIAL COMPARING, NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY VERSUS THE SAME NEOADJUVANT CHEMOTHERAPY FOLLOWED BY STANDARD RADIOTHERAPY ASSOCIATED WITH DAILY HYDROXYUREA IN THE TREATMENT OF LOCALLY ADVANCED UNDIFFERENTIATED CARCINOMA NASOPHARYNGEAL TYPE. [Active, not recruiting]
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) [Active, not recruiting]
Adherence to Hydroxyurea in Children With Sickle Cell Anemia [Completed]
A Study of MKC-442 in Combination With Other Anti-HIV Drugs [Completed]
Phase 2 Study of Montelukast for the Treatment of Sickle Cell Anemia [Recruiting]
Safety and Effectiveness of a Combination Anti-HIV Drug Treatment [Completed]
Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract [Recruiting]
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer [Recruiting]
Safety and Durability ofTenofovir and a Cell Cycle Agent for Viral Suppression [Completed]
Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study [Terminated]
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer [Suspended]
Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises [Active, not recruiting]
Fluorouracil, Hydroxyurea, Cetuximab and Twice-daily Intensity Radiation Therapy for Advanced Head and Neck Cancer [Completed]
Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer [Active, not recruiting]
Combination Drug Treatment of Pediatric HIV Infection [Completed]
Pediatric Hydroxyurea in Sickle Cell Anemia (PED HUG) [Completed]
Radiation Therapy in Treating Patients With Glioblastoma [Completed]
Study of Clotrimazole and Hydroxyurea in Patients With Sickle Cell Syndromes [Completed]
Phase I/II Randomized Study of Hydroxyurea With or Without Clotrimazole in Patients With Sickle Cell Anemia [Completed]
A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia. [Completed]
Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available. [Recruiting]
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) [Recruiting]
A Multicenter Study of Intensive Concomitant Chemoradiotherapy With Filgrastim (GCSF) for Patients With Locoregionally Advanced Head and Neck Cancer [Completed]
VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia [Completed]
Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer [Completed]
Clopidogrel and Aspirin for the Treatment of Polycythemia Vera [Withdrawn]
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia [Active, not recruiting]
Dermal HIV-1 Immunization During Anti-retroviral Therapy Followed by Repeated Treatment Interruptions [Completed]
Study to Determine the Safety and Efficacy of Ruxolitinib (INCB018424) in Patients With Polycythemia Vera or Essential Thrombocythemia [Active, not recruiting]
Reduced Intensity Transplant Conditioning Regimen for Severe Thalassemia [Active, not recruiting]
Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer [Active, not recruiting]
Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD) [Recruiting]
Medication Adherence in Youth With Sickle Cell Disease (SCD) [Completed]
Decision Aid for Therapeutic Options In Sickle Cell Disease [Recruiting]
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE) [Active, not recruiting]
|
